DeepCure Raises $24.6 Million in Series A-1 Round
DeepCure, a Boston, MA-based company developing novel, small molecule therapeutics powered by AI and automation of chemistry, has raised $24.6 million in Series A-1 funding, bringing its total raised to over $72 million.
DeepCure, a Boston, MA-based company developing novel, small molecule therapeutics powered by AI and automation of chemistry, has raised $24.6 million in Series A-1 funding, bringing its total raised to over $72 million.
Investors
The round was led by IAG Capital Partners (IAG), with participation from the company's existing investors.
IAG Capital Partners is a private investment group based in Charleston, South Carolina. The firm seeks investments in early-stage companies and partners with innovative leaders to build companies that will impact our lives and the world.
DeepCure Use of Funds
The company will use the funds to further develop its cutting-edge technology and to advance its immunology and inflammation pipeline toward clinical trials.
About DeepCure
Founded by researchers at MIT, DeepCure has built a generative AI and physics-based engine to innovate the discovery of small molecule therapies for challenging targets. The engine can map potential interaction sites on the surface of proteins and design novel, synthesizable molecules with lead-like properties. Additionally, DeepCure has developed the most advanced automated chemistry synthesis platform to increase the speed, number, and diversity of molecules that are tested. Its vision is to use AI-driven discovery to create better molecules and faster cures for every disease-relevant protein target.
Funding Details
Company: DeepCure
Raised: $24.6M
Round: Series A-1
Funding Month: April 2024
Lead Investors: IAG Capital Partners
Additional Investors:
Company Website: https://deepcure.ai/
Software Category: AI Engine
